Shares of Eli Lilly and Co (NYSE:LLY) have been assigned an average recommendation of “Hold” from the twenty ratings firms that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and ten have given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $92.22.
A number of research analysts have recently commented on the company. Argus upgraded Eli Lilly and from a “hold” rating to a “buy” rating and increased their price target for the company from $85.52 to $115.00 in a research note on Friday, January 5th. Credit Suisse Group reiterated a “hold” rating on shares of Eli Lilly and in a research note on Wednesday, December 13th. BMO Capital Markets set a $73.00 price target on Eli Lilly and and gave the company a “sell” rating in a research note on Tuesday, December 12th. Morgan Stanley increased their price target on Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 21st. Finally, Zacks Investment Research cut Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday, October 30th.
In related news, SVP Susan Mahony sold 36,585 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the sale, the senior vice president now directly owns 54,885 shares in the company, valued at $4,729,989.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the stock in a transaction on Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the completion of the sale, the insider now owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Insiders sold 251,088 shares of company stock valued at $22,041,236 over the last 90 days. 0.20% of the stock is currently owned by company insiders.
Eli Lilly and (NYSE LLY) traded up $0.04 during midday trading on Monday, reaching $86.10. The company’s stock had a trading volume of 1,674,500 shares, compared to its average volume of 2,756,557. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66. Eli Lilly and has a 12-month low of $74.00 and a 12-month high of $89.09. The company has a market capitalization of $94,780.00, a PE ratio of 41.00, a PEG ratio of 1.62 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. During the same period in the prior year, the company earned $0.88 earnings per share. The company’s quarterly revenue was up 9.0% on a year-over-year basis. equities research analysts expect that Eli Lilly and will post 4.22 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be issued a $0.5625 dividend. This represents a $2.25 dividend on an annualized basis and a yield of 2.61%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio is presently 99.05%.
ILLEGAL ACTIVITY NOTICE: “Brokerages Set Eli Lilly and Co (LLY) PT at $92.22” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://www.com-unik.info/2018/01/11/brokerages-set-eli-lilly-and-co-lly-pt-at-92-22.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.